Healthcare
Pro Medicus Limited(PMCUF)
Live Price
Offline$118.13
-0.82% today
1Y Change
-39.39%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $14.22B
- Revenue Growth
- +31.8%
- EPS Growth
- +39.2%
- Dividend Yield
- 0.5%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pro Medicus Limited (PMCUF) is a Healthcare stock with a market cap of $14.22B and listed on OTC. The stock last traded around $118.13 and down 39.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +31.8%, EPS growth of +39.2%, a dividend yield of 0.5%. What stands out right now is revenue +31.8%, EPS +39.2%, free cash flow +38.1% with operating margin 74.2% and ROIC 25.9%. The dividend is present but secondary, with a yield around 0.5%. Valuation already assumes a fairly strong business story at P/E 60.6 and price/sales 59.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines PMCUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+31.8% vs +7.6% peer median
Operating Margin
Above sector median
+74.2% vs +19.4% peer median
P/E
Above sector median
60.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Feb 11, 2026 with an EPS surprise of +147.0% and a revenue surprise of -2.9%.
The operating story is still moving forward
Revenue is running at +31.8% and EPS at +39.2%, with operating margin around 74.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 19, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -8.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 11, 2026 | +147.0% | -23.1% | -28.0% | -23.0% |
2025 Aug 12, 2025 | +3.7% | -4.4% | -0.2% | -4.0% |
2025 Feb 13, 2025 | +0.7% | -0.1% | +2.4% | +20.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMCUF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PMCUF Max Drawdown
-64.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PMCUF and SPY.
Company Overview
Pro Medicus Limited
Other OTC
Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
- Leadership
- Sam Aaron Hupert
- IPO Date
- Jan 8, 2021
- Employees
- 75
- Street Address
- 450 Swan Street
- Mailing
- Richmond, VIC, 3121
- Region
- Richmond, VIC, AU
- Reporting Currency
- USD
- Investor Line
- 61 3 9429 8800
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 60.6
- EV/EBITDA
- 74.9
- Price/Sales
- 59.1
- Price/Book
- 36.6
Growth
- Revenue
- +31.8%
- EPS
- +39.2%
- Free Cash Flow
- +38.1%
Profitability
- Gross Margin
- 78.4%
- Operating Margin
- 74.2%
- Net Margin
- 97.6%
- ROE
- 72.7%
- ROIC
- 25.9%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 6.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.